Medications for PTSD
What medications are used for PTSD, where prazosin fits for nightmares, and why benzodiazepines are usually avoided.
First-line options
SSRIs
Two SSRIs carry FDA approval for PTSD.
Sertraline at 50 to 200 mg. Trials show reduction in the three core PTSD symptom clusters (re-experiencing, avoidance, hyperarousal). Effect size is modest. Onset is 4 to 6 weeks or longer, and higher doses are often needed than for depression.
Paroxetine at 20 to 60 mg. Similar evidence base. The sexual side effects, weight gain, and discontinuation syndrome make it less popular first-line despite the FDA indication.
Beyond the two approved options, fluoxetine has reasonable off-label evidence for PTSD and is used commonly. Escitalopram is used off-label with some data.
For the class picture, see the SSRI class page.
SNRIs
Venlafaxine XR at 75 to 300 mg has evidence for PTSD comparable to the SSRIs and is often considered alongside them for first-line treatment. Not FDA-approved for PTSD but widely used off-label.
Duloxetine has some evidence and is a reasonable option, particularly when chronic pain is part of the picture.
Trauma-focused therapy alongside
The medications above have modest effect sizes on their own. Trauma-focused psychotherapy (prolonged exposure therapy, cognitive processing therapy, EMDR) has larger effect sizes and durable benefit. In practice, medication and therapy together are the standard, and either alone is a partial answer. For patients unable to engage in trauma-focused work early, medication as a starting point makes sense with the goal of adding therapy when tolerable.
Second-line and augmentation
Prazosin for nightmares
Prazosin is an alpha-1 antagonist used off-label for PTSD-related nightmares and sleep disturbance. Starting dose is typically 1 mg at bedtime, titrating up to 5 to 15 mg. Some patients respond well, some don't. The 2018 VA PACT trial was negative for the overall PTSD population, which cooled enthusiasm compared to earlier positive studies, but many clinicians still use prazosin because subgroups clearly respond. It remains a reasonable trial for prominent nightmares.
Orthostatic hypotension is the main side effect, and dose has to be titrated slowly. Not a solution for insomnia without nightmares.
Atypical antipsychotics as adjunct
For SSRI-refractory PTSD, adding an atypical antipsychotic has evidence with limits.
Risperidone at 1 to 4 mg has some trials showing benefit as SSRI adjunct, particularly for hyperarousal and re-experiencing. The 2011 VA study was negative for overall improvement but showed some benefit on specific symptom clusters.
Quetiapine at 100 to 400 mg has smaller trials suggesting benefit as adjunct, particularly for sleep disturbance and hyperarousal.
Atypical antipsychotic monotherapy for PTSD is not supported by the evidence. Adjunctive use is second-line after SSRI or SNRI has been optimized.
Mirtazapine
Mirtazapine at 15 to 45 mg has small trials in PTSD, particularly for the sleep and appetite dimensions. Reasonable as adjunct or monotherapy in patients who can't tolerate SSRIs.
Nefazodone
Nefazodone has evidence in PTSD but comes with a boxed warning for hepatotoxicity that limits use.
Other approaches
Topiramate has some data for PTSD, particularly with comorbid alcohol use disorder. Lamotrigine has small evidence for PTSD. Gabapentin has some off-label use for anxiety and sleep dimensions.
Cannabinoid options (nabilone, cannabis) have been studied for PTSD sleep and nightmares with mixed results. Not standard treatment.
MDMA-assisted psychotherapy has ongoing FDA review; approval has been delayed. Not routinely available.
When to consider a different approach
Treatment-resistant PTSD
If SSRI or SNRI at adequate dose and duration (10 to 12 weeks or longer, since PTSD often responds more slowly than depression) hasn't produced adequate response, options include switching class, augmenting with an atypical, adding prazosin for sleep and nightmares, and increasing the intensity of trauma-focused therapy. Referral to a PTSD specialty clinic or a VA program is reasonable.
Comorbid substance use
PTSD and substance use disorder co-occur frequently. Treating both is standard. Naltrexone, acamprosate, or buprenorphine (depending on the substance) work alongside PTSD treatment. Benzodiazepines are usually avoided because of dependence risk on top of the substance use.
Comorbid TBI
Traumatic brain injury and PTSD often coexist in veterans and others. Some medications (particularly those with strong anticholinergic profiles) can worsen cognitive function post-TBI. Sertraline and prazosin are usually well-tolerated. Higher-anticholinergic options are usually avoided.
Complex PTSD or dissociative features
The evidence base for medications in complex PTSD (associated with prolonged interpersonal trauma) is thinner. SSRIs are still the default. Trauma-focused therapy adapted for complex presentations (STAIR, phased approach with skills training first) is often the anchor.
Special considerations
Benzodiazepines: usually avoided
Multiple lines of evidence suggest benzodiazepines don't help PTSD long-term and may worsen it. They can interfere with the extinction learning that trauma-focused therapy relies on. Chronic benzodiazepine use in PTSD is associated with worse outcomes in some studies. VA and DoD guidelines specifically recommend against benzodiazepines for PTSD.
The exception is short-term, low-dose use for acute anxiety or panic in patients who haven't responded to alternatives, ideally as a bridge rather than chronic treatment.
For patients already on chronic benzodiazepines, tapering is difficult and should be gradual, ideally with alternative anxiolytic support (SSRI, prazosin for sleep, CBT).
Atypical antipsychotic monotherapy: usually avoided
The evidence doesn't support atypical antipsychotics as monotherapy for PTSD. Adjunctive use is reasonable for refractory cases; monotherapy is not.
Pregnancy
Sertraline is the most-studied SSRI in pregnancy. Paroxetine is avoided in the first trimester because of small cardiac malformation signal. Untreated PTSD in pregnancy has its own risks (poor prenatal care, substance use, poor birth outcomes). Individual risk-benefit conversations are the norm. See the pregnancy safety reference.
Older adults
Older adults with PTSD (often from earlier-life trauma or ongoing losses) benefit from the same treatment framework, with attention to Beers Criteria. Sertraline and escitalopram at lower doses, prazosin at lower doses (with careful orthostasis monitoring), and mirtazapine at low doses are all reasonable. Avoid benzodiazepines and heavily anticholinergic agents. See Beers Criteria.
Comorbid depression
Depression coexists with PTSD frequently. SSRIs cover both. Bupropion is a reasonable adjunct if fatigue is prominent and anxiety is not dominant.
Comorbid insomnia
Insomnia in PTSD is often driven by hyperarousal and nightmares. Prazosin for nightmares. Trazodone at bedtime for sleep initiation. DORAs (suvorexant, lemborexant, daridorexant) are reasonable options with less dependence risk. See medications for insomnia.
What tips the choice
- Newly diagnosed PTSD, no strong comorbidity signal: sertraline or paroxetine (or venlafaxine XR off-label). Start typical antidepressant dose, expect slow titration and 8 to 12 week trial before judging response.
- Prominent nightmares and sleep disturbance: add prazosin. Consider trazodone or DORA on top for sleep initiation.
- Refractory to SSRI or SNRI at adequate dose: switch class, or augment with an atypical antipsychotic (risperidone or quetiapine).
- Comorbid depression: SSRI or SNRI covers both. Consider adjunctive bupropion if fatigue is prominent.
- Comorbid substance use: treat both. Naltrexone, acamprosate, or buprenorphine for the SUD; SSRI for the PTSD. Avoid benzodiazepines.
- Comorbid anxiety and panic: SSRI or SNRI is the anchor. Avoid benzodiazepines except as short-term bridging.
- Older adult: sertraline or escitalopram at lower dose. Prazosin cautiously with orthostasis monitoring.
- Veteran with combat-related PTSD: same algorithm. VA-DoD guidelines specifically recommend against benzodiazepines and against atypical antipsychotic monotherapy, and specifically recommend trauma-focused therapy.
- Trauma-focused therapy tolerable: the therapy is the main event, and the medication supports it.
- Trauma-focused therapy not tolerable now: medication as starting point, with the plan to add therapy when tolerable.
Common questions
Why not benzodiazepines for PTSD? Benzodiazepines reduce anxiety in the moment, but in PTSD they can interfere with the emotional processing that trauma-focused therapy relies on. Long-term benzodiazepine use in PTSD is associated with worse outcomes in some studies. VA and DoD guidelines recommend against them for PTSD. There's still a role for short-term, low-dose PRN use in specific situations, but chronic daily benzodiazepines aren't the answer for PTSD.
Do medications really work for PTSD? They work, but modestly. Effect sizes for SSRIs in PTSD are smaller than for depression. Response rates are around 60% for at least some symptom improvement, with full remission less common. Combined treatment (medication plus trauma-focused therapy) tends to outperform either alone.
What about prazosin for nightmares? Prazosin has been used for PTSD-related nightmares for over 20 years. Early trials were positive; the large 2018 VA PACT trial was negative for the overall PTSD population. Many clinicians still use it because some patients clearly respond. It's a reasonable trial for prominent nightmares, especially when sleep disturbance is a major complaint. Orthostatic hypotension is the main side effect and dose has to be titrated slowly.
How long do I take a PTSD medication? Guidelines suggest continuing an effective medication for at least 12 months after full remission before considering a taper. For chronic PTSD, longer courses (years) are common. Discontinuing medication should be gradual and coordinated with a prescriber. Trauma-focused therapy often reduces the need for medication over time.
What if I want to try MDMA-assisted therapy? MDMA-assisted psychotherapy has been studied in FDA-registered trials and showed strong results, but the FDA declined approval in 2024. As of now, it's not routinely available outside research settings. Ketamine and psilocybin for PTSD are areas of active research.
Sources
This guide draws on current prescribing information, treatment guidelines, and public health references. It is reviewed for clinical accuracy and updated as guidance changes.
- VA/DoD Clinical Practice Guideline for the Management of Posttraumatic Stress Disorder.
- American Psychiatric Association. Practice guideline for the treatment of patients with acute stress disorder and PTSD.
- Raskind MA et al. Trial of prazosin for post-traumatic stress disorder in military veterans.
- National Institute of Mental Health. Post-traumatic stress disorder.
THE KNOWLEDGE PATH
Walk this topic outward.
- GUIDE Medications for PTSD (current)
- CLASS SSRIs
- MEDICATION Sertraline (Zoloft)
- CONDITION Major Depressive Disorder (on Shrinkopedia)
- CARE Consider depression evaluation at shrinkMD
The Knowledge Path is a curated walk. Every step is one decision away from the next.
Managing a medication needs a prescriber
Any psychiatric medication has to be started and adjusted by a clinician who can follow you over time. If you don't have a prescriber, our guides section explains the options, including in-person care and telepsychiatry, and how to choose between them.